Tempus AI Posts 83% Revenue Growth, Stock Drops 7% Anyway
NEW YORK, April 24 —
Tempus AI grew revenue 83% year over year, beat EPS estimates, and still lost 7% of its market value.
- Revenue hit $1.3bn TTM on 83% YoY growth, with EPS coming in above consensus
- Shares trade at a negative 571.8x forward P/E — the company still isn't expected to turn a profit soon
- New USC partnership covers 1.5 million annual patient visits, but no disclosed revenue terms yet
What Actually Happened
Tempus delivered the kind of quarter most companies would frame and hang on the wall. Revenue growth of 83% is legitimately fast for a company already running at $1.3bn TTM. The EPS beat, while still deeply negative, showed losses narrowing faster than analysts expected.
The USC deal is the splashier headline. The University of Southern California health system will deploy Tempus's AI-driven precision medicine tools across its network, covering 1.5 million patient visits per year. That's a major academic medical center betting its clinical workflows on the platform. For a company trying to prove its tech works at hospital scale, this is the strongest validation yet.
So why did the stock drop? At $51.7 per share with a negative forward P/E of 571.8x, Tempus was already priced for perfection. An earnings beat and a partnership announcement are good. They just aren't good enough when the stock already reflected a best-case scenario.
The Catch
The USC partnership sounds transformative, but there are no disclosed financial terms. "1.5 million patient visits" is a volume number, not a revenue number. Healthcare AI partnerships have a long history of generating impressive press releases and modest invoices. The gap between "deployed across a system" and "billing per patient" can take years to close.
The deeper problem is profitability. A negative 571.8x forward P/E means Wall Street doesn't expect real earnings anytime soon. Revenue growth of 83% is excellent. But investors have watched enough high-growth healthcare tech stories to know that growth without a visible path to positive earnings eventually exhausts even patient capital. Tempus needs to show that each new dollar of revenue improves the margin structure, not just the top line.
Bottom Line
This is a stock where the business is hitting its targets and the valuation is punishing it for not hitting them faster. If you believe precision medicine AI is a generational shift in healthcare delivery, Tempus is building one of the stronger platforms. If you need to see profits before you believe, nothing in this quarter changes that. The numbers to watch next quarter: whether revenue growth holds above 70%, and whether management puts a dollar figure on the USC deal.
Tempus AI doesn't have a Basis Report yet. Generate a full TEM analysis here to dig into the financials.
Basis Report does not hold positions in securities discussed. This is not investment advice.